Get started
Author

Yiru Long

PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way
2022 · Xiaolu Yu, Yiru Long, et al. · Journal for ImmunoTherapy of Cancer · 65
PDF
Different Immunoregulation Roles of Activin A Compared With TGF-β
2022 · Fanglin Li, Yiru Long, et al. · Frontiers in Immunology · 23
PDF
INHBA promotes tumor growth and induces resistance to PD-L1 blockade by suppressing IFN-γ signaling
2024 · Fang-lin Li, Long-hua Gu, et al. · Acta Pharmacologica Sinica · 22
CoVac501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunity
2022 · Yiru Long, Jianhua Sun, et al. · Cell Discovery · 22
PDF
A nanobody-enzyme fusion protein targeting PD-L1 and sialic acid exerts anti-tumor effects by C-type lectin pathway-mediated tumor associated macrophages repolarizing
2025 · Yongliang Tong, Runqiu Chen, et al. · International Journal of Biological Macromolecules · 19
Suppression of Tumor or Host Intrinsic CMTM6 Drives Antitumor Cytotoxicity in a PD-L1–Independent Manner
2022 · Yiru Long, Runqiu Chen, et al. · Cancer Immunology Research · 15
PDF
Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
2022 · Yiru Long, Xiaolu Yu, et al. · Frontiers in Immunology · 14
PDF
GFPBW1, a β-glucan from Grifola frondosa as vaccine adjuvant: APCs activation and maturation
2024 · Xiang He, Jiang-ling Lu, et al. · Acta Pharmacologica Sinica · 12
PDF
Construction of stable membranal CMTM6-PD-L1 full-length complex to evaluate the PD-1/PD-L1-CMTM6 interaction and develop anti-tumor anti-CMTM6 nanobody
2022 · Xiao-min Jia, Yi-ru Long, et al. · Acta Pharmacologica Sinica · 12
PDF
Towards a comprehensive view of the herpes B virus
2023 · Jiangling Lu, Yiru Long, et al. · Frontiers in Immunology · 11
PDF
A Potent Oral Sialylation Inhibitor Augments the Immunotherapy in Pancreatic Ductal Adenocarcinoma
2025 · Jiahui Mou, Runqiu Chen, et al. · ACS Central Science · 7
PDF
The PD-L1 and TLR7 dual-targeting nanobody-drug conjugate exerts potent antitumor efficacy by orchestrating innate and adaptive immune responses
2021 · Xiaolu Yu, Yiru Long, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 3
PDF
Non-blocking anti-PD-L1 nanobody conjugated to TLR7 agonist mediates macrophage/NK cell-associated antitumor effects
2025 · Chao Hu, Chen Chen, et al. · Acta Pharmaceutica Sinica B · 2
STING agonist-mediated endothelial cell activation drives NK cells and neutrophils-dependent pulmonary inflammation
2026 · Chen Chen, Yaqi Zhao, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1
PDF
A nanobody-enzyme fusion protein targeting PD-L1 and sialic acid exerts anti-tumor effects by affecting tumor associated macrophages
2024 · Yongliang Tong, Runqiu Chen, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1
INHBA/Activin A promotes tumor growth and induces resistance to anti-PD-L1 therapy by suppressing IFN-γ signaling
2023 · Fanglin Li, Longhua Gu, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1
PDF
CMTM6/PD-L1-targeted AAV promotes anti-tumor immune responses and chemotherapy responsiveness
2026 · Runqiu Chen, Xiaoyu Pang, et al. · Frontiers in Immunology
PDF
Lipid metabolic reprogramming of macrophage by host APOBEC3 deficiency enhances anti-tumor immunity
2026 · Yuqi Yang, Fanglin Li, et al. · British Journal of Cancer
CMTM6 maintains B cell-intrinsic membrane CD40 stability to regulate anti-tumor immunity
2026 · Runqiu Chen, Wenlong Chang, et al. · Acta Pharmaceutica Sinica B
PDF
CKLF‐like MARVEL transmembrane domain‐containing superfamily 8 (CMTM8) promotes Notch signalling to maintain CD8 + T cell‐ and NK cell‐dependent tumour immune escape
2026 · Fanglin Li, Longhua Gu, et al. · British Journal of Pharmacology
CTLA-4 inhibitors drive colitis through metabolic reprogramming-mediated Treg/Th17 imbalance
2026 · Zhiying Li, Shanna Wu, et al. · bioRxiv (Cold Spring Harbor Laboratory)
AI-aided design of multi-epitope peptide vaccine elicits cellular and humoral immunity to broad Omicron subvariants
2026 · Zhang Kai, Wang Gan-Gao, et al. · 动物学研究
PDF
Supplementary Data from Suppression of Tumor or Host Intrinsic CMTM6 Drives Antitumor Cytotoxicity in a PD-L1–Independent Manner
2025 · Yiru Long, Runqiu Chen, et al.
PDF
CMTM6 maintains B cell-intrinsic CD40 expression to regulate anti-tumor immunity
2024 · Yiru Long, Runqiu Chen, et al. · bioRxiv (Cold Spring Harbor Laboratory)
PDF
Data from Suppression of Tumor or Host Intrinsic CMTM6 Drives Antitumor Cytotoxicity in a PD-L1–Independent Manner
2023 · Yiru Long, Runqiu Chen, et al.
Works count: 29
Citation count: 230
H-index: 10
I10-index: 10
Year
Topic
Type